- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06133972
Étude d'extension de phase 3 pour évaluer l'innocuité à long terme de l'ianalumab chez les participants atteints de lupus érythémateux systémique (extension SIRIUS-SLE). (SIRIUS-SLE LTE)
A Randomized, Double-blind, Placebo-controlled Extension Study, Followed by a Study Treatment Withdrawal or Open-label Period, to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The purpose of this extension study is to evaluate long-term safety and tolerability of ianalumab administered s.c. monthly or quarterly, compared to monthly placebo, in adolescent and adult participants with anti-nuclear antibody (ANA)-positive systemic lupus erythematosus of moderate-to-severe disease activity, who have completed either CVAY736F12301 (SIRIUS-SLE 1) or CVAY736F12302 (SIRIUS-SLE 2) core studies.
This extension study will last up to 7 years and includes the following three treatment periods:
- a 3-year double-blind, randomized, placebo-controlled treatment period, evaluating the safety and efficacy of ianalumab or placebo (Period 1);
- followed by a 2-year treatment period evaluating safety and efficacy of treatment withdrawal and open-label ianalumab administered s.c. monthly.
- and an up to 2-year open-label, safety monitoring period (Period 3).
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Accès étendu
Contacts et emplacements
Coordonnées de l'étude
- Nom: Novartis Pharmaceuticals
- Numéro de téléphone: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Sauvegarde des contacts de l'étude
- Nom: Novartis Pharmaceuticals
- Numéro de téléphone: +41613241111
- E-mail: novartis.email@novartis.com
Lieux d'étude
-
-
-
Umhlanga, Afrique du Sud, 4320
- Recrutement
- Novartis Investigative Site
-
-
Gauteng
-
Pretoria, Gauteng, Afrique du Sud, 0002
- Recrutement
- Novartis Investigative Site
-
-
Western Cape
-
Cape Town, Western Cape, Afrique du Sud, 7500
- Recrutement
- Novartis Investigative Site
-
Cape Town, Western Cape, Afrique du Sud, 7405
- Recrutement
- Novartis Investigative Site
-
Somerset West, Western Cape, Afrique du Sud, 7130
- Recrutement
- Novartis Investigative Site
-
-
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Allemagne, 50937
- Retiré
- Novartis Investigative Site
-
-
Saxony
-
Leipzig, Saxony, Allemagne, 04103
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Caba, Argentine, C1015ABO
- Actif, ne recrute pas
- Novartis Investigative Site
-
Caba, Argentine, C1427CCL
- Recrutement
- Novartis Investigative Site
-
San Miguel de Tucumán, Argentine, T4000AXL
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Buenos Aires
-
La Plata, Buenos Aires, Argentine, B1900AWT
- Recrutement
- Novartis Investigative Site
-
Quilmes, Buenos Aires, Argentine, 1878
- Recrutement
- Novartis Investigative Site
-
San Miguel, Buenos Aires, Argentine, B1663GKT
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Tucumán Province
-
San Miguel, Tucumán Province, Argentine, T4000CBC
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
-
-
Queensland
-
Maroochydore, Queensland, Australie, 4558
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brésil, 40323-010
- Recrutement
- Novartis Investigative Site
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brésil, 29055-450
- Recrutement
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brésil, 40150-150
- Recrutement
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brésil, 30150-221
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Paraná
-
Curitiba, Paraná, Brésil, 80030-110
- Recrutement
- Novartis Investigative Site
-
-
Rio de Janeiro
-
Niterói, Rio de Janeiro, Brésil, 24020-096
- Actif, ne recrute pas
- Novartis Investigative Site
-
Rio de Janeiro, Rio de Janeiro, Brésil, 22211-230
- Recrutement
- Novartis Investigative Site
-
-
São Paulo
-
Barretos, São Paulo, Brésil, 14784-400
- Recrutement
- Novartis Investigative Site
-
São Paulo, São Paulo, Brésil, 04038-002
- Actif, ne recrute pas
- Novartis Investigative Site
-
São Paulo, São Paulo, Brésil, 01244-030
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
-
-
-
Sofia, Bulgarie, 1431
- Recrutement
- Novartis Investigative Site
-
-
Bulgaria
-
Plovdiv, Bulgaria, Bulgarie, 4002
- Recrutement
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1L7
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Quebec
-
Rimouski, Quebec, Canada, G5L 5T1
- Recrutement
- Novartis Investigative Site
-
-
-
-
Los Ríos Region
-
Valdivia, Los Ríos Region, Chili, 5110683
- Recrutement
- Novartis Investigative Site
-
-
RM
-
Santiago, RM, Chili, 7500588
- Recrutement
- Novartis Investigative Site
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chili, 7500710
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Beijing, Chine, 100730
- Recrutement
- Novartis Investigative Site
-
Beijing, Chine, 100069
- Recrutement
- Novartis Investigative Site
-
Shanghai, Chine, 200001
- Recrutement
- Novartis Investigative Site
-
Xinxiang, Chine, 453099
- Recrutement
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510080
- Recrutement
- Novartis Investigative Site
-
Guangzhou, Guangdong, Chine, 510000
- Recrutement
- Novartis Investigative Site
-
Shantou, Guangdong, Chine, 515000
- Recrutement
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210008
- Recrutement
- Novartis Investigative Site
-
Suzhou, Jiangsu, Chine, 215004
- Recrutement
- Novartis Investigative Site
-
-
Jiangxi
-
Nanchang, Jiangxi, Chine, 330006
- Actif, ne recrute pas
- Novartis Investigative Site
-
Pingxiang, Jiangxi, Chine, 337000
- Recrutement
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, Chine, 130021
- Recrutement
- Novartis Investigative Site
-
-
Shandong
-
Linyi, Shandong, Chine, 276100
- Recrutement
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610041
- Recrutement
- Novartis Investigative Site
-
-
Xinjiang
-
Ürümqi, Xinjiang, Chine, 830001
- Recrutement
- Novartis Investigative Site
-
-
Zhejiang
-
Ningbo, Zhejiang, Chine, 315016
- Recrutement
- Novartis Investigative Site
-
Wenzhou, Zhejiang, Chine, 325000
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Bogotá, Colombie, 111211
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Antioquia
-
Medellín, Antioquia, Colombie, 050001
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombie, 080020
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Cundinamarca
-
Chía, Cundinamarca, Colombie, 250001
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombie, 680003
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombie, 760046
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Gwangju, Corée du Sud, 61469
- Complété
- Novartis Investigative Site
-
Seoul, Corée du Sud, 06591
- Recrutement
- Novartis Investigative Site
-
Seoul, Corée du Sud, 04763
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Espagne, 08035
- Recrutement
- Novartis Investigative Site
-
Madrid, Espagne, 28034
- Recrutement
- Novartis Investigative Site
-
Valencia, Espagne, 46014
- Recrutement
- Novartis Investigative Site
-
-
A Coruna
-
Santiago Compostela, A Coruna, Espagne, 15706
- Recrutement
- Novartis Investigative Site
-
-
Barcelona
-
Badalona, Barcelona, Espagne, 08916
- Recrutement
- Novartis Investigative Site
-
-
Cantabria
-
Santander, Cantabria, Espagne, 39008
- Recrutement
- Novartis Investigative Site
-
-
Catalonia
-
Barcelona, Catalonia, Espagne, 08003
- Recrutement
- Novartis Investigative Site
-
-
Madrid
-
San Sebastian Reyes, Madrid, Espagne, 28702
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Montpellier, France, 34295
- Recrutement
- Novartis Investigative Site
-
Paris, France, 75014
- Actif, ne recrute pas
- Novartis Investigative Site
-
Paris, France, 75013
- Actif, ne recrute pas
- Novartis Investigative Site
-
Toulouse, France, 31059
- Recrutement
- Novartis Investigative Site
-
Toulouse, France, 31054
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Guatemala City, Guatemala, 01010
- Recrutement
- Novartis Investigative Site
-
-
Departamento de Guatemala
-
Guatemala City, Departamento de Guatemala, Guatemala, 01010
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hongrie, 1134
- Recrutement
- Novartis Investigative Site
-
Gyula, Hongrie, 5700
- Recrutement
- Novartis Investigative Site
-
Zalaegerszeg, Hongrie, 8900
- Recrutement
- Novartis Investigative Site
-
-
Fejér
-
Székesfehérvár, Fejér, Hongrie, 8000
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
New Delhi, Inde, 110075
- Recrutement
- Novartis Investigative Site
-
-
Gujarat
-
Ahmedabad, Gujarat, Inde, 380015
- Recrutement
- Novartis Investigative Site
-
Ahmedabad, Gujarat, Inde, 380006
- Recrutement
- Novartis Investigative Site
-
-
Kerala
-
Kozhikode, Kerala, Inde, 673008
- Recrutement
- Novartis Investigative Site
-
-
Maharashtra
-
Kolhāpur, Maharashtra, Inde, 416001
- Recrutement
- Novartis Investigative Site
-
Nagpur, Maharashtra, Inde, 441108
- Recrutement
- Novartis Investigative Site
-
Nashik, Maharashtra, Inde, 422101
- Recrutement
- Novartis Investigative Site
-
Pune, Maharashtra, Inde, 411001
- Recrutement
- Novartis Investigative Site
-
Pune, Maharashtra, Inde, 411007
- Recrutement
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Inde, 110060
- Recrutement
- Novartis Investigative Site
-
-
New Delhi
-
New Delhi, New Delhi, Inde, 110029
- Recrutement
- Novartis Investigative Site
-
-
Uttarakhand
-
Dehradun, Uttarakhand, Inde, 248001
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Haifa, Israël, 3109601
- Actif, ne recrute pas
- Novartis Investigative Site
-
Ramat Gan, Israël, 5265601
- Recrutement
- Novartis Investigative Site
-
-
-
-
FE
-
Cona, FE, Italie, 44124
- Recrutement
- Novartis Investigative Site
-
-
PD
-
Padova, PD, Italie, 35128
- Recrutement
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italie, 56126
- Recrutement
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italie, 00152
- Recrutement
- Novartis Investigative Site
-
-
TO
-
Torino, TO, Italie, 10128
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Miyazaki, Japon, 8891692
- Recrutement
- Novartis Investigative Site
-
Osaka, Japon, 5458586
- Recrutement
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japon, 4578510
- Actif, ne recrute pas
- Novartis Investigative Site
-
Nagoya, Aichi-ken, Japon, 4578511
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japon, 0608648
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japon, 2360004
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Miyagi
-
Sendai, Miyagi, Japon, 9838512
- Recrutement
- Novartis Investigative Site
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japon, 1138519
- Recrutement
- Novartis Investigative Site
-
Chuo Ku, Tokyo, Japon, 1048560
- Recrutement
- Novartis Investigative Site
-
Fuchū, Tokyo, Japon, 1838524
- Actif, ne recrute pas
- Novartis Investigative Site
-
Shinjuku-ku, Tokyo, Japon, 1608582
- Actif, ne recrute pas
- Novartis Investigative Site
-
tabashi City, Tokyo, Japon, 1738610
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
-
-
-
Braga, Le Portugal, 4710-243
- Recrutement
- Novartis Investigative Site
-
Lisbon, Le Portugal, 1050-034
- Recrutement
- Novartis Investigative Site
-
-
-
-
Perak
-
Ipoh, Perak, Malaisie, 30450
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
México, Mexique, 07760
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Guanajuato
-
León, Guanajuato, Mexique, 37160
- Recrutement
- Novartis Investigative Site
-
-
Jalisco
-
Guadalajara, Jalisco, Mexique, 44160
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Mexico City
-
Mexico City, Mexico City, Mexique, 06700
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Michoacán
-
Morelia, Michoacán, Mexique, 58000
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexique, 97070
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Bydgoszcz, Pologne, 85-065
- Recrutement
- Novartis Investigative Site
-
Bydgoszcz, Pologne, 85-168
- Recrutement
- Novartis Investigative Site
-
Bytom, Pologne, 41 902
- Recrutement
- Novartis Investigative Site
-
Warsaw, Pologne, 00-874
- Recrutement
- Novartis Investigative Site
-
Warsaw, Pologne, 04-141
- Recrutement
- Novartis Investigative Site
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Pologne, 52-210
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Brasov, Roumanie, 500283
- Recrutement
- Novartis Investigative Site
-
Bucharest, Roumanie, 011172
- Recrutement
- Novartis Investigative Site
-
-
Cluj
-
Cluj-Napoca, Cluj, Roumanie, 400006
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Bratislava, Slovaquie, 811 08
- Actif, ne recrute pas
- Novartis Investigative Site
-
Košice, Slovaquie, 040 01
- Actif, ne recrute pas
- Novartis Investigative Site
-
-
-
-
-
Kaohsiung City, Taïwan, 833
- Recrutement
- Novartis Investigative Site
-
Taichung, Taïwan, 40447
- Recrutement
- Novartis Investigative Site
-
Taichung, Taïwan, 407219
- Recrutement
- Novartis Investigative Site
-
Taipei, Taïwan, 10002
- Recrutement
- Novartis Investigative Site
-
Taipei, Taïwan, 11217
- Recrutement
- Novartis Investigative Site
-
Taoyuan, Taïwan, 33305
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Brno, Tchéquie, 638 00
- Recrutement
- Novartis Investigative Site
-
Prague, Tchéquie, 128 00
- Recrutement
- Novartis Investigative Site
-
Uherské Hradiště, Tchéquie, 686 01
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thaïlande, 10400
- Recrutement
- Novartis Investigative Site
-
Bangkok, Thaïlande, 10700
- Recrutement
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, Thaïlande, 90110
- Recrutement
- Novartis Investigative Site
-
-
Thailand
-
Muang, Thailand, Thaïlande, 12120
- Recrutement
- Novartis Investigative Site
-
-
-
-
Alabama
-
Anniston, Alabama, États-Unis, 36207
- Recrutement
- Pinnacle Research Group Llc
-
Chercheur principal:
- Vishala L Chindalore
-
Contact:
- Ruby Fields
- Numéro de téléphone: +1 256 236 0055
- E-mail: rfields@pinnacletrials.com
-
-
California
-
Burbank, California, États-Unis, 91505
- Recrutement
- Providence Medical Center
-
Chercheur principal:
- Sue Chung
-
Contact:
- Sandra Figueroa
- Numéro de téléphone: +1 818 869 7067
- E-mail: Sandra.Figueroa@providence.org
-
La Palma, California, États-Unis, 90623
- Recrutement
- Advanced Medical Research
-
Chercheur principal:
- Gerald Ho
-
Contact:
- Reza Azadegan
- Numéro de téléphone: +1 714 752 6587
- E-mail: razadegan@advmedresearch.com
-
Westlake Village, California, États-Unis, 91361
- Actif, ne recrute pas
- Millennium Clinical Trials
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- University of Colorado Denver
-
Chercheur principal:
- Christopher Striebich
-
Contact:
- Chong Pedrick
- E-mail: chong.pedrick@cuanschutz.edu
-
-
Florida
-
Clearwater, Florida, États-Unis, 33765
- Recrutement
- Clinical Res Of W Florida
-
Chercheur principal:
- Robert Levin
-
Contact:
- Jessica Mayfield
- Numéro de téléphone: +1 727 466 0078
- E-mail: JMayfield@crwf.com
-
Cooper City, Florida, États-Unis, 33024
- Recrutement
- GNP Research
-
Chercheur principal:
- Mark Jaffe
-
Contact:
- Melissa Pierce
- Numéro de téléphone: +1 754 248 3589
- E-mail: melissa@gnpresearch.com
-
Homestead, Florida, États-Unis, 33033
- Recrutement
- Homestead Assoc In Research Inc
-
Chercheur principal:
- Gilberto Seco
-
Contact:
- Mario Hernandez
- Numéro de téléphone: 13052460873
- E-mail: mhernandez@associatesinresearch.com
-
Plantation, Florida, États-Unis, 33324
- Recrutement
- IRIS Research and Development
-
Chercheur principal:
- Guillermo Valenzuela
-
Contact:
- Jhon Galindo
- Numéro de téléphone: +1 954 476 2338
- E-mail: jgalindo@irisrheumatology.com
-
Tampa, Florida, États-Unis, 33603
- Recrutement
- Clinical Research of West Florida Inc
-
Chercheur principal:
- John Carter
-
Contact:
- Abby Carlson
- Numéro de téléphone: +1 813 870 1292
- E-mail: ACarlson@crwf.com
-
-
Georgia
-
Lawrenceville, Georgia, États-Unis, 30044
- Recrutement
- Parris and Associates Rheumatology
-
Chercheur principal:
- Glenn Parris
-
Contact:
- Mannai Coutermarsh
- Numéro de téléphone: +17709621616#8334
- E-mail: m.coutermarsh@parrisandassociates.net
-
-
Illinois
-
Skokie, Illinois, États-Unis, 60076
- Complété
- Robert A Hozman MD SC
-
Willowbrook, Illinois, États-Unis, 60527
- Recrutement
- Willow Rheumatology Wellness
-
Chercheur principal:
- Angela R Crowley
-
Contact:
- Lubna Ali
- E-mail: lali@willowrheum.com
-
-
Louisiana
-
Lake Charles, Louisiana, États-Unis, 70601
- Recrutement
- Accurate Clinical Research
-
Chercheur principal:
- Enrique Mendez
-
Contact:
- Machell Broussard
- E-mail: mbroussard@accurateclinicalresearch.com
-
New Orleans, Louisiana, États-Unis, 70112
- Actif, ne recrute pas
- UMC New Orleans
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21201
- Actif, ne recrute pas
- University Of Maryland
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48202
- Recrutement
- Henry Ford Health
-
Chercheur principal:
- Alireza Meysami
-
Contact:
- Jenna Hudy
- Numéro de téléphone: +1 313 916 1984
- E-mail: jhudy1@hfhs.org
-
Grand Blanc, Michigan, États-Unis, 48439
- Recrutement
- Ahmed Arif Medical Research Center
-
Chercheur principal:
- Ali Karrar
-
Contact:
- Iman Abdelrahman
- Numéro de téléphone: +1 810 953 8700
- E-mail: iman@aamrc.net
-
-
Ohio
-
Middleburg Heights, Ohio, États-Unis, 44130
- Recrutement
- Paramount Med Rsrch and Consult LLC
-
Chercheur principal:
- Isam Diab
-
Contact:
- Denine Ryan
- Numéro de téléphone: +1 440 891 9395
- E-mail: deniner64@gmail.com
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15213
- Recrutement
- University Of Pittsburgh
-
Chercheur principal:
- Andreea Coca
-
Contact:
- Kathryn Lemon
- E-mail: kal128@pitt.edu
-
-
Tennessee
-
Jackson, Tennessee, États-Unis, 38305
- Recrutement
- West Tennessee Research Institute
-
Chercheur principal:
- Jacob A Aelion
-
Contact:
- Rachel Williams
- Numéro de téléphone: 17316330119
- E-mail: rwilliams@arthritisclinic.org
-
Memphis, Tennessee, États-Unis, 38119
- Recrutement
- Shelby Research LLC
-
Chercheur principal:
- Ramesh C Gupta
-
Contact:
- Suvarna Konangula
- Numéro de téléphone: +1 901 681 9670
- E-mail: shelbyres1999@outlook.com
-
-
Texas
-
Bellaire, Texas, États-Unis, 77401
- Recrutement
- Novel Research LLC
-
Chercheur principal:
- Wajeeha Yousaf
-
Contact:
- Hassan Khan
- E-mail: khan@novelresearch.net
-
League City, Texas, États-Unis, 77573
- Recrutement
- Accurate Clinical Research
-
Chercheur principal:
- Sabeen Najam
-
Contact:
- Mariela Martinez
- Numéro de téléphone: +1 281 422 7179
- E-mail: mmartinez@accurateclinicalresearch.com
-
Red Oak, Texas, États-Unis, 75154
- Recrutement
- Epic Medical Research
-
Chercheur principal:
- Sunny Patel
-
Contact:
- Harshini Potluri
- Numéro de téléphone: +1 469 206 2642
- E-mail: hpotluri@epicmedresearch.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
- Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants <18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
- Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.
- In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.
Key Exclusion Criteria:
- Use of prohibited therapies.
- Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
- Plans for administration of live vaccines during the study period.
- Pregnant or nursing (lactating) women.
Other protocol-defined inclusion/exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Ianalumab monthly
Ianalumab s.c. monthly |
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Autres noms:
|
|
Expérimental: Ianalumab quarterly
Ianalumab s.c. quarterly |
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Autres noms:
|
|
Comparateur placebo: Placebo monthly
Placebo s.c. monthly |
Placebo s.c. monthly |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of treatment-emergent Adverse events/Serious Adverse events
Délai: through study completion, up to approximately 324 weeks
|
Assessment of long-term safety and tolerability of ianalumab |
through study completion, up to approximately 324 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response
Délai: up to Week 324
|
SRI-4 response is defined as:
|
up to Week 324
|
|
Proportion of participants who achieved Definition of Remission in SLE (DORIS) response
Délai: up to Week 324
|
DORIS is defined as:
|
up to Week 324
|
|
Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index
Délai: up to Week 324
|
SLICC/ACR Damage Index is a measure of cumulative damage due to SLE |
up to Week 324
|
|
Average daily dose of corticosteroids administered
Délai: up to Week 324
|
Evaluating the effect of ianalumab on corticosteroids intake |
up to Week 324
|
|
Annualized BILAG moderate or severe flare rate
Délai: up to Week 324
|
Annualized BILAG moderate or severe flare rate where moderate BILAG flare is defined as 2 or more new BILAG-2004 B items, and severe BILAG flare is defined as 1 or more new BILAG-2004 A items, compared to the previous visit |
up to Week 324
|
|
Ianalumab serum concentrations during treatment and follow-up after last dose
Délai: up to Week 324
|
To characterize the Pharmacokinetics (PK) of ianalumab |
up to Week 324
|
|
Incidence and titer of anti-ianalumab antibodies in serum (ADA assay) over time.
Délai: up to Week 324
|
To characterize the immunogenicity of ianalumab |
up to Week 324
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CVAY736F12301E1
- 2023-505929-14-00 (Identificateur de registre: EU CT NUMBER)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .